Lineage Cell Therapeutics
Carlsbad, California, United States · Biotechnology, Manufacturing, Therapeutics · 70 employees
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or 'off-the-shelf,' cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical
Funding history
- Funding Round — $21.0M — Nov 2025
- Funding Round — $12.0M — Aug 2025
- Funding Round — $35.0M — Mar 2021
Recent signals
- Jan 06, 2026: Lineage Cell Therapeutics Enters Partnership with Factor Bioscience to Deliver Gene-edited Hypoimmune Cell Line.
- Nov 12, 2025: Raised $21.0M
- Nov 12, 2025: SEC 8-K (2.01): On November 12, 2025, Lineage Cell Therapeutics, Inc. completed a significant equity transaction by selling 12,000,000 common shares to Janus Henderson Investors at a purchase price of $1.75 per share under its at-the-market offering program. This sale resulted in gross proceeds of $21 million for the company, prior to the deduction of any fees and expenses. This transaction marks a crucial step for Lineage as it seeks to bolster its financial position and fund its ongoing development initiatives, thus potentially enhancing shareholder value.
- Aug 26, 2025: Raised $12.0M
- Mar 10, 2025: Lineage Cell Therapeutics Signs Services Agreement with Genentech
- Mar 08, 2021: Raised $35.0M
See plans & pricing → Track Lineage Cell Therapeutics ’s funding, hiring, and signals — with verified contacts — on Fundz.